Aditxt (NASDAQ:ADTX – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Institutional and Insider Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Aditxt has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Profitability
This table compares Aditxt and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Sol-Gel Technologies | -1,115.39% | -38.80% | -33.29% |
Valuation and Earnings
This table compares Aditxt and Sol-Gel Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.01 | -$41.71 million | ($100,788.35) | -0.00 |
| Sol-Gel Technologies | $19.39 million | 9.00 | -$6.13 million | ($5.23) | -10.20 |
Sol-Gel Technologies has higher revenue and earnings than Aditxt. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Aditxt and Sol-Gel Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 270.13%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Aditxt.
Summary
Sol-Gel Technologies beats Aditxt on 13 of the 15 factors compared between the two stocks.
About Aditxt
Aditxt, Inc. is a biotechnology company focused on developing technologies for immune-system monitoring and modulation. Its AditxtScore platform is designed to measure and profile immune responses, with potential applications in tracking immune health and supporting personalized care. The company has also pursued immune-reprogramming approaches intended to promote immune tolerance in areas such as autoimmune disease, allergies and transplant rejection. Through its operating businesses and strategic initiatives, Aditxt has expanded its activities into diagnostics and other health-related technologies.
About Sol-Gel Technologies
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
